Quarterly and annual results disclosed under 8-K Item 2.02.
Aardvark Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 23, 2026, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the quarter and full year ended December 31, 2025, and providing pipeline and business updates.”
Surrozen, Inc./DE reported fourth quarter and full year 2025 results: revenue $0.5 million and $3.5 million for the quarter and year ended December 31, 2025.
“On March 23, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025.”
Public Policy Holding Company, Inc. reported Q4 2025 results: revenue $49.9 million, net income GAAP Net Loss of $(15.2) million, EPS GAAP Basic and diluted loss per share of $(0.86).
“Q4 revenue increased 27.8% over the prior period to $49.9 million”
Public Policy Holding Company, Inc. reported the year ended December 31, 2025 results: revenue $186.5 million, net income GAAP Net Loss of $(39.0) million, EPS GAAP Basic and diluted loss per share of $(2.37).
“filing. --- EX-99.1 (EX-99.1) --- Public Policy Holding Company, Inc. Announces Full Year 2025 Financial Results Revenue Growth Driving Group to Record EBITDA • Revenue of $186.5 million with organic revenue growth of 6.2% • Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of 24.3% • Successfully completed our $45.8 million”
PARKERVISION INC reported the year ended December 31, 2025 results: net income net loss of $7.4 million, EPS $0.06 per common share.
“ParkerVision reported a net loss for the year ended December 31, 2025 of $7.4 million, or $0.06 per common share, compared to a net loss of $14.5 million, or $0.16 per common share for the year ended December 31, 2024.”
CapsoVision, Inc reported preliminary financial results for fourth quarter and full year ended December 31, 2025.
“On March 20, 2026, the Company issued a press release announcing certain of its preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.”
Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
“On March 20, 2026, Milestone Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025”
FiEE, Inc. reported fourth quarter and full-year ended December 31, 2025 results: revenue approximately $6.2 million, net income approximately $1.1 million.
“and full-year ended December 31, 2025. Operational and Financial Highlights for the Year Ended December 31, 2025 ● Revenue increased 867.9% year-over-year to approximately $6.2 million. The increase in revenue primarily reflects the Company’s strategic transition from legacy hardware operations to SaaS solutions, with a new business model focusing on”
RELMADA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.
“Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update”
Phunware, Inc. reported the fourth quarter and year ended December 31, 2025 results: revenue $0.8 million, net income $2.1 million, EPS ($0.11).
“monetize their global audiences, today reported financial results for the fourth quarter and year ended December 31, 2025. Financial Highlights • Net revenue increased 33% to $0.8 million in Q4 2025, as compared to $0.6 million in Q4 2024. • Gross margin improved to 57.7% in Q4 2025, as compared to 23.3% in Q4 2024, a 3,443 basis point improvement. • Net loss”
CHEETAH NET SUPPLY CHAIN SERVICE INC. reported the year ended December 31, 2025 results: revenue $1,288,536.
“provider, today reported results for the year ended December 31, 2025 and provided a corporate update. For the year ended December 31, 2025, the Company reported revenue of $1,288,536 from its logistics and warehousing business, compared to $455,805 in 2024, representing an increase of $832,731, or 182.7%. The Company recorded an operating loss of $4,579,576”
ECOLAB INC. reported full-year 2026 results: EPS $8.43 to $8.63. Guidance reaffirmed.
“For the full-year 2026, excluding the impact of CoolIT, Ecolab continues to expect adjusted diluted earnings per share in the $8.43 to $8.63 range”
ECOLAB INC. reported first quarter 2026 results: EPS $1.69 to $1.71. Guidance initiated.
“Ecolab expects first quarter 2026 adjusted diluted earnings per share in the $1.69 to $1.71 range”
SAN JUAN BASIN ROYALTY TRUST reported the production month of January 2026 results: revenue $6,352,562 of total revenue from the Subject Interests for the production month of January 2026, consisting of $6,220,44.
“Hilcorp reported $6,352,562 of total revenue from the Subject Interests for the production month of January 2026, consisting of $6,220,448 of gas revenues, $132,114 of oil revenues. For the Subject Interests, Hilcorp reported $4,301,489 of production costs (excluding the balance of excess production costs) for the production month of January 2026, consisting of $3,155,715 of lease operating expenses, $643,665 of severance taxes, and $502,110 of capital costs.”
UNITED STATES ANTIMONY CORP updated its fiscal year 2025 guidance (reaffirmed).
“On March 19, 2026, United States Antimony Corporation (“USAC”, “US Antimony”, or the “Company”) issued a press release reporting its financial results for fiscal year 2025.”
Intellicheck, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $6,635,000, net income $1,552,000 or $0.08 per diluted share, EPS $0.08 per diluted share.
“announced its financial results for the fourth quarter and full-year ended December 31, 2025. Total revenue for the fourth quarter ended December 31, 2025 grew 12% to a record $6,635,000 compared to $5,936,000 in the same period of 2024. Fourth quarter SaaS revenue grew 12% and totaled $6,620,000 compared to $5,913,000 in the same period of 2024. Total revenue for”
FEDEX CORP reported fiscal year 2026 results: EPS $19.30 to $20.10. Guidance raised.
“FedEx is revising its fiscal 2026 outlook, and now expects: • A 6.0% to 6.5% revenue growth rate year over year, compared to the prior forecast of 5% to 6% growth; • Diluted earnings per share of $16.05 to $16.85 before the MTM retirement plans accounting adjustments compared to the prior forecast of $14.80 to $16.00”
FEDEX CORP reported fiscal quarter ended February 28, 2026 results: revenue $24.0 billion, net income $1.26 billion, EPS $5.25.
“adjusted (non-GAAP) Revenue $24.0 billion $24.0 billion $22.2 billion $22.2 billion Operating income $1.35 billion $1.62 billion $1.29 billion $1.51 billion Operating margin 5.6% 6.7% 5.8% 6.8% Net income $1.06 billion $1.26 billion $0.91 billion $1.09 billion Diluted EPS $4.41 $5.25 $3.76 $4.51”
FEDEX CORP reported fiscal quarter ended February 28, 2026 results: revenue $24.0 billion, net income $1.06 billion, EPS $4.41.
“February 28 (adjusted measures exclude the items listed below): Fiscal 2026 Fiscal 2025 As Reported (GAAP) Adjusted (non-GAAP) As Reported (GAAP) Adjusted (non-GAAP) Revenue $24.0 billion $24.0 billion $22.2 billion $22.2 billion Operating income $1.35 billion $1.62 billion $1.29 billion $1.51 billion Operating margin 5.6% 6.7% 5.8% 6.8% Net income $1.06 billion”
Marker Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $12.2 million.
“Marker reported a net loss of $12.2 million for the year ended December 31, 2025”
CURIS INC reported Year ended December 31, 2025 results: revenue $9.4 million, net income $7.6 million, EPS $0.58.
“per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024. Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge”
CURIS INC reported Fourth Quarter 2025 results: revenue $1.1 million, net income $19.4 million, EPS $1.23.
“for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® . Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited”
PEDEVCO CORP reported fourth quarter and full year ended December 31, 2025 results: revenue $22.5 – 23.5 Million.
“Fourth Quarter and Full Year 2025 Results Following Transformational Juniper Merger Record Preliminary* Q4 and Full Year 2025 Financial Results Q4 Revenue Rose over 2x to $22.5 – 23.5 Million Q4 Adj. EBITDA Grew Nearly 3x to $14.5 – 15.5 Million Q4 Average Daily Production grew ~140% to 5 – 5.5 Mboe/d Earnings Results and 2026 Financial Outlook to Be”
GOLD RESOURCE CORP reported financial results for the year ending December 31, 2025.
“Gold Resource Corporation (the “Company”) issued a news release reporting its production and unaudited financial results for the year ending December 31, 2025.”
Larimar Therapeutics, Inc. reported the fourth quarter of 2025 and for the year ended December 31, 2025 results: net income $62.5 million, or $0.73 per share of common stock.
“On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025.”
SELLAS Life Sciences Group, Inc. reported financial results for the full year ended December 31, 2025.
“SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.”
Eledon Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025 was $45.6 million, or $0.52 per basic share of common stock, EPS $0.52 per basic share of common stock.
“On March 19, 2026, Eledon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
Titan Machinery Inc. reported fourth quarter and fiscal year ended January 31, 2026 results: revenue $641.8 million, net income net loss was $36.2 million, with loss per diluted share of $1.59, EPS $1.59.
“a pivotal step in positioning Titan for the next phase of the cycle." Fiscal 2026 Fourth Quarter Results Consolidated Results For the fourth quarter of fiscal 2026, revenue was $641.8 million, compared to $759.9 million in the fourth quarter of last year. Equipment revenue was $501.5 million for the fourth quarter of fiscal 2026, compared to $621.8 million in the”
ASSEMBLY BIOSCIENCES, INC. reported the year ended December 31, 2025 results: revenue $72.3 million, net income Net loss attributable to common stockholders was $6.1 million, EPS $0.55 per basic and diluted share.
“Year-End 2025 Financial Results • Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of the year ended December 31, 2024. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, compared to $28.5 million in 2024. The increase reflects the increase in collaboration funding. • Research and development expenses were $64.8 million for the year ended December 31, 2025, compared to $55.9 million in 2024. The increase is largely driven by an increase in spending on the HPI program, as both ABI-1179 and ABI-5366 saw significant enrollment in their respective Phase 1b clinical studies during the current year. • General and administrative expenses were $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024. The increase was primar”
Accenture plc updated its fiscal 2026 ended February 28, 2026 guidance (reaffirmed).
“Accenture plc (“Accenture”) issued a news release announcing financial results for its second quarter of fiscal 2026, which ended on February 28, 2026.”
CALERES INC reported fiscal year 2025 (52 weeks ended January 31, 2026) results: revenue $2.8 billion, net income GAAP net loss was $6.7 million, EPS $0.21.
“Adjusted excluding Stuart Weitzman ($0.06) $0.33 Fiscal Year 2025 Results (52 weeks ended January 31, 2026, compared to 52 weeks ended February 1, 2025) ● Net sales were $2.8 billion, up 1.3% versus fiscal 2024, including Stuart Weitzman. o Famous Footwear segment net sales decreased 3.6% versus last year, with comparable sales down 2.3%. o Brand Portfolio”
CALERES INC reported the quarter ended January 31, 2026 results: revenue $695.1 million, net income GAAP net loss was $22.7 million, EPS $0.70.
“Brands, eCommerce and International drive growth. Caleres completes Stuart Weitzman integration. Sam Edelman Saige Studded Ankle Boot ● Reported fourth quarter net sales of $695.1 million, up 8.7%. o Brand Portfolio sales increased 20.3%, with organic sales up 1.5%. o Continued growth across all channels of our Brand Portfolio business, supplemented by continued”
Genie Energy Ltd. updated its quarter and full year ended December 31, 2025 guidance (reaffirmed).
“On March 19, 2026, the Registrant distributed over a wire service and posted to the investor relations page of its website (www.genie.com), an earnings release announcing its select preliminary estimated unaudited results of operations for the quarter and full year ended December 31, 2025.”
Tenon Medical, Inc. reported full year 2025 results: revenue $3.9 million, net income net loss was $12.6 million, EPS $1.70 per share.
“Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~ ~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior Year ~ ~”
Tenon Medical, Inc. reported fourth quarter 2025 results: revenue $1.5 million, net income net loss was $2.8 million, EPS $0.29 per share.
“RELEASE OF TENON MEDICAL, INC., DATED MARCH 19, 2026 Exhibit 99.1 Tenon ® Medical Reports Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~ ~ Record”
Odysight.ai Inc. reported full year ended December 31, 2025 results: revenue $3.0 million.
“operations.” Einav Brenner, Chief Financial Officer of Odysight.ai added: “Our full year 2025 results reflect a period of investment in our growth. While total revenues of $3.0 million including $1.7 million from the wind-down of our legacy Fortune 500 medical contract, our core PdM and CBM platform revenues grew approximately 23% year-over-year, focused on the”
Theravance Biopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.
“On March 19, 2026, Theravance Biopharma, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and full year ended December 31, 2025 and a business update.”
DULUTH HOLDINGS INC. reported the fiscal year ended February 1, 2026 results: net income Net loss reduced to $16.2 million compared to a net loss of $43.6 million in the prior year., EPS $0.47 loss. Guidance initiated.
“Net loss reduced to $16.2 million compared to a net loss of $43.6 million in the prior year.”
DULUTH HOLDINGS INC. reported the fiscal Fourth Quarter ended February 1, 2026 results: revenue $215.9 million, net income $7.8 million, EPS $0.22. Guidance initiated.
“core, lasting products our customers value most, and building on the momentum the team has created.” Operating Results for the Fourth Quarter ended February 1, 2026 Net sales of $215.9 million, a decrease of $25.4 million or 10.5%, in the three months ended February 1, 2026 compared to $241.3 million in the three months ended February 2, 2025. Direct-to-consumer net”
Moleculin Biotech, Inc. reported financial results for the year ended December 31, 2025.
“Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026”
Datavault AI Inc. reported the fiscal year ended December 31, 2025 results: revenue $39.1 million. Guidance reaffirmed.
“Revenue increased to $39.1 million for the fiscal year ended December 31, 2025”
Datavault AI Inc. reported the fourth quarter ended December 31, 2025 results: revenue $33.8 million, net income $661 thousand. Guidance reaffirmed.
“Revenue for the fourth quarter ended December 31, 2025 was $33.8 million”
Eton Pharmaceuticals, Inc. reported the fourth quarter and twelve months ended December 31, 2025 results: revenue $21.3 million, EPS basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.. Guidance raised.
“--- EX-99.1 2 ex_889836.htm EXHIBIT 99.1 ex_889836.htm Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results ● Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 ● Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and”
Mereo BioPharma Group plc reported financial results for the full year ended December 31, 2025.
“Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.”
Acrivon Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively..
“Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively.”
Torrid Holdings Inc. reported full year fiscal 2026 results: revenue Net sales between $940 million and $960 million. Guidance initiated.
“For the full year fiscal 2026 the Company expects: • Net sales between $940 million and $960 million.”
Torrid Holdings Inc. reported first quarter of fiscal 2026 results: revenue Net sales between $236 million and $244 million. Guidance initiated.
“For the first quarter of fiscal 2026 the Company expects: • Net sales between $236 million and $244 million.”
Torrid Holdings Inc. reported fourth quarter ended January 31, 2026 results: revenue Net sales decreased 14.3% to $236.2 million, net income Net loss of $8.1 million, EPS ($0.08) per share.
“Net sales decreased 14.3% to $236.2 million compared to $275.6 million for the fourth quarter of last year.”
Torrid Holdings Inc. reported fiscal year ended January 31, 2026 results: revenue Net sales decreased 9.4% to $1,000.1 million, net income Net Loss of $7.0 million, EPS ($0.07) per share.
“Net sales decreased 9.4% to $1,000.1 million compared to $1,103.7 million last year.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.